Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%
KB

Krystal Biotech, Inc. (KRYS)

NASDAQ • Healthcare

$332.56
-$2.5 (-0.7%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$336.56
Day Range$332.02 - $337.03
Avg. Volume (3M)283.9K
Market Cap$9.8B
P/E Ratio40.2
52 Week Range
$178.61$382.54
Next EarningsIn 32 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$119.2M100%
Gross Profitminus cost of goods$112.7M95%
Operating Incomeminus R&D and overhead$58.4M49%
Net Incomeminus taxes and the rest$54.7M46%

In plain terms: out of every $100 in revenue, Krystal Biotech, Inc. keeps $46 as net profit.

Fundamentals & Financials

Revenue (TTM)
$440.4M
Net Income (TTM)
$241.4M
EPS (TTM)
$8.27
ROA (TTM)
16.09%
Current Ratio
8.32

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+4.9%Q1 2026$1.7
+26.2%Q2 2026$1.83
+5.3%Q3 2026$1.79
Next

Nov 2

in 32 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +5.3%

Krystal Biotech’s earnings topped expectations while revenue trailed consensus in the second fiscal quarter of 2026, reported August 3, 2026. Revenue rose 24.1% to roughly $119.2 million (up from about $96.0 million a year ago), but on the consensus comparison it came in at $119.2 million versus the $120.9 million estimate (-1.4%, trailed). EPS was $1.79, up 38.8% from $1.29 a year ago, and it topped the $1.70 estimate (+5.3%). Profitability stayed elevated, with gross profit of about $112.8 million translating to a gross margin of roughly 95%, and operating income of roughly $58.4 million with operating margin near 49%. Net income increased 42.9% to about $54.8 million (up from roughly $38.3 million a year ago), and the company generated operating cash flow of about $74.8 million during the quarter. For the next period, consensus calls for EPS of $1.91 on revenue of $129.6 million.

View full earnings history

About Krystal Biotech, Inc.

Krystal Biotech, Inc. is a NASDAQ-listed biotechnology company developing redosable gene therapies in the United States, with a focus on severe orphan diseases. The company generated $389.1 million in FY2025 revenue and centers its programs on genetic medicines for dermatology and other serious conditions.

Name
Krystal Biotech, Inc.
CEO
Krish S. Krishnan
Website
www.krystalbio.com
Industry
Healthcare
Year Founded
2015
Employees
295

Today's Snapshot

AI-generated

The day ended with KRYS 0.8% lower at 332.56, in line with a weaker sector.

Trading Volume

Below 10d avg (319.7K)

263.9K

vs S&P 500 Today

Underperforming Market

-0.94%

Updated: September 30, 2026 at 20:21 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
KRYS is neutral on balance, caught between short-term weakness and a healthier longer-term profile: the price sits below several short- and medium-term moving averages but remains above the 200-day averages, and momentum indicators are soft with RSI in the low 40s and a negative MACD. Trend strength is weak with ADX near 12, and volatility is moderate with an ATR around 3.2% of price. On-balance volume is not supportive, while pivot levels are roughly overhead. Technical takeaway: Neutral — short-term pressures offset by longer-term support and muted trend strength.
All signals
  • EMA (5 indicators)$295.87 - $342.21
    Sell
  • RSI (14)42.28
    Neutral
  • Stochastic %K (14, 3, 3)13.88
    Buy
  • MACD Level (12, 26)-2.58
    Sell

Peers & Related Assets

ARWRArrowhead Pharmaceuticals, Inc.
$65.45-1.2%
PTGXProtagonist Therapeutics, Inc.
$140.89-0.1%
TGTXTG Therapeutics, Inc.
$55.78-0.7%
PCVXVaxcyte, Inc.
$56.9+0.4%
ALKSAlkermes plc
$40.52-0.7%
TFXTeleflex Incorporated
$125.04-1.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.